Opportunity Information: Apply for PAR 11 059
Apply for PAR 11 059
- The National Institutes of Health in the environment health income security and social services sector is offering a public funding opportunity titled "Developmental Pharmacology (R21)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.113 Environmental Health 93.242 Mental Health Research Grants 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders 93.865 Child Health and Human Development Extramural Research.
- This funding opportunity was created on Aug 7, 2013 and posted on Dec 3, 2010.
- Applicants must submit their applications by Aug 7, 2013. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $200,000.00 in funding.
- Eligible applicants include: Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses County governments City or township governments Native American tribal governments (Federally recognized) Special district governments Others (see text field entitled Additional Information on Eligibility for clarification) Small businesses State governments Native American tribal organizations (other than Federally recognized tribal governments) Private institutions of higher education Public and State controlled institutions of higher education Independent school districts Public housing authorities/Indian housing authorities.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Developmental Pharmacology (R21) grant opportunity (Funding Opportunity Number PAR-11-059) is an NIH discretionary funding announcement led by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), with participation from other NIH Institutes. It supports investigator-initiated research focused on developmental pharmacology, meaning how medicines and biological therapeutics behave in the body at different stages of human development. The central theme is ontogeny, or how biological systems change from fetal life through infancy, childhood, and adolescence, and how those changes influence drug response, safety, and effectiveness. The announcement is designed to encourage multidisciplinary projects that connect basic mechanistic biology to translational questions that can ultimately improve dosing, reduce adverse events, and strengthen evidence-based treatment for pediatric and adolescent populations.
Scientifically, the opportunity emphasizes research on age-dependent differences in drug disposition and drug action. This includes how drug-metabolizing enzymes develop and vary across stages of growth, how drug transporters influence absorption and distribution in immature organs, and how receptors and signaling pathways mature in ways that can change pharmacologic sensitivity or toxicity. In practical terms, applicants are being asked to propose studies that explain why a drug might be processed faster or slower in a neonate compared to a teenager, or why the same concentration of a medication could produce different therapeutic effects or side effects depending on developmental stage. Projects can be basic or translational, and the intent is to stimulate work that clarifies mechanisms and generates data that can inform pediatric pharmacotherapy, including questions of developmental biology that underlie pharmacokinetics (what the body does to the drug) and pharmacodynamics (what the drug does to the body).
The funding mechanism is the NIH R21, which is typically used for exploratory and developmental research projects that are early-stage, novel, or higher-risk, often aimed at establishing feasibility, generating preliminary data, or opening up a new research direction. For this specific opportunity, the listed award ceiling is $200,000, and there is no cost sharing or matching requirement. The funding activity categories and CFDA numbers associated with the announcement span several mission areas, including Environmental Health (93.113), Mental Health Research Grants (93.242), Neurosciences and Neurological Disorders (93.853), and Child Health and Human Development Extramural Research (93.865), reflecting the cross-cutting relevance of developmental pharmacology to multiple clinical and scientific domains.
Eligibility is broad and includes many types of domestic and international organizations. Eligible applicants include public and private institutions of higher education, nonprofit organizations with or without 501(c)(3) status, for-profit organizations (other than small businesses as a separate category), small businesses, and a wide range of governmental entities such as state governments, county governments, city or township governments, special district governments, independent school districts, and public housing authorities/Indian housing authorities. Tribal entities are explicitly included, covering federally recognized Native American tribal governments as well as other tribal organizations. The announcement also allows participation from foreign (non-U.S.) organizations and regional organizations, and it highlights inclusion of institutions and groups such as Historically Black Colleges and Universities (HBCUs), Hispanic-Serving Institutions, Alaska Native and Native Hawaiian Serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, and U.S. territories or possessions.
Key administrative details indicate the opportunity was posted December 3, 2010, with an original closing date of September 7, 2014, and an archived date of September 8, 2013, with internal dates in the record noting creation on August 7, 2013 and a current closing date shown as August 7, 2013. The authoritative announcement is hosted through the NIH Grants Guide at the provided link (http://grants.nih.gov/grants/guide/pa-files/PAR-11-059.html). For technical issues accessing or linking to the announcement, the contact listed is the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV.
Overall, this opportunity is aimed at advancing the science needed to understand and predict how developmental stage shapes drug metabolism, transport, receptor engagement, and downstream signaling, ultimately supporting safer and more effective pharmacologic treatment across the pediatric age spectrum.
Developmental Pharmacology (R21) Grant (PAR-11-059) - FAQs
What is the Developmental Pharmacology (R21) funding opportunity?
It is an NIH discretionary funding announcement (Funding Opportunity Number PAR-11-059) that supports investigator-initiated research in developmental pharmacology, with leadership by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and participation from other NIH Institutes.
What does "developmental pharmacology" mean in this announcement?
Developmental pharmacology focuses on how medicines and biological therapeutics behave in the body at different stages of human development, and how developmental changes influence drug response, safety, and effectiveness from fetal life through infancy, childhood, and adolescence.
What is the central scientific theme of this opportunity?
The central theme is ontogeny: how biological systems change across developmental stages and how those changes affect pharmacologic response, including drug metabolism, transport, receptor engagement, signaling, therapeutic effects, and toxicity.
What kinds of research questions does this opportunity encourage?
The announcement encourages studies that explain age-dependent differences in drug disposition and drug action, such as why a drug may be processed faster or slower in a neonate compared to a teenager, or why the same drug concentration could lead to different benefits or side effects depending on developmental stage.
What scientific areas are emphasized for developmental differences in drug disposition?
Emphasized areas include development and variation of drug-metabolizing enzymes across growth stages, and the role of drug transporters in absorption and distribution in immature organs.
What scientific areas are emphasized for developmental differences in drug action?
Emphasized areas include maturation of receptors and signaling pathways that can alter pharmacologic sensitivity, therapeutic response, or toxicity at different developmental stages.
Is the opportunity limited to basic science, or can it include translational research?
Projects may be basic or translational. The stated intent is to connect basic mechanistic biology with translational questions that can improve dosing, reduce adverse events, and strengthen evidence-based treatment for pediatric and adolescent populations.
How does the opportunity relate to pharmacokinetics and pharmacodynamics?
It explicitly targets developmental biology questions that underlie pharmacokinetics (what the body does to the drug) and pharmacodynamics (what the drug does to the body), with an emphasis on how these processes change with developmental stage.
What grant mechanism is used for this funding opportunity?
The funding mechanism is the NIH R21, which is typically used for exploratory and developmental projects that are early-stage, novel, or higher-risk, and often aimed at establishing feasibility, generating preliminary data, or opening a new research direction.
What is the maximum award amount mentioned for this opportunity?
The listed award ceiling is $200,000.
Is cost sharing or matching required?
No. The opportunity states there is no cost sharing or matching requirement.
Which NIH Institute is leading this announcement?
The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is identified as the lead Institute, with participation from other NIH Institutes.
Which mission areas or CFDA numbers are associated with the announcement?
The announcement is associated with multiple CFDA numbers spanning several mission areas: Environmental Health (93.113), Mental Health Research Grants (93.242), Neurosciences and Neurological Disorders (93.853), and Child Health and Human Development Extramural Research (93.865).
Who is eligible to apply?
Eligibility is broad and includes many domestic and international organization types, including public and private institutions of higher education; nonprofit organizations (with or without 501(c)(3) status); for-profit organizations; small businesses; and a wide range of governmental entities.
What types of U.S. governmental entities are eligible?
Eligible governmental applicants include state governments, county governments, city or township governments, special district governments, independent school districts, and public housing authorities/Indian housing authorities.
Are Tribal entities eligible?
Yes. Tribal entities are explicitly included, covering federally recognized Native American tribal governments and other tribal organizations.
Are foreign (non-U.S.) organizations allowed to apply?
Yes. The announcement allows participation from foreign (non-U.S.) organizations and regional organizations.
Does the opportunity highlight any specific institution types for inclusion?
Yes. It highlights inclusion of institutions and groups such as Historically Black Colleges and Universities (HBCUs), Hispanic-Serving Institutions, Alaska Native and Native Hawaiian Serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, and U.S. territories or possessions.
What is the main purpose or intended impact of the supported research?
The opportunity aims to advance the science needed to understand and predict how developmental stage shapes drug metabolism, transport, receptor engagement, and downstream signaling, ultimately supporting safer and more effective pharmacologic treatment across the pediatric age spectrum.
When was this funding opportunity posted, and what are the dates noted in the record?
The opportunity was posted on December 3, 2010. The record also notes an original closing date of September 7, 2014, an archived date of September 8, 2013, and internal dates indicating creation on August 7, 2013 with a current closing date shown as August 7, 2013.
Where is the authoritative announcement posted?
The authoritative announcement is hosted through the NIH Grants Guide at http://grants.nih.gov/grants/guide/pa-files/PAR-11-059.html.
Who should be contacted for technical issues accessing or linking to the announcement?
For technical issues, the listed contact is the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV.
Browse more opportunities from the same category: Environment Health Income Security and Social Services
Next opportunity: Disaster Resilience for Rural Communities
Previous opportunity: Developmental Pharmacology (R03)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 11 059
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 11 059) also looked into and applied for these:
| Funding Opportunity |
|---|
| Countermeasures Against Chemical Threats (CounterACT) Cooperative Research Projects (U01) Apply for PAR 11 155 Funding Number: PAR 11 155 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Autism Centers of Excellence Centers (P50) Apply for RFA HD 12 195 Funding Number: RFA HD 12 195 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: $1,500,000 |
| Autism Centers of Excellence Networks (R01) Apply for RFA HD 12 196 Funding Number: RFA HD 12 196 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: $2,000,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 11 059", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.